• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 10-K filed by Cosmos Health Inc.

    4/15/25 4:36:30 PM ET
    $COSM
    Other Pharmaceuticals
    Health Care
    Get the next $COSM alert in real time by email

    Unavailable

    Get the next $COSM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $COSM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $COSM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Cosmos Health Inc.

      SC 13G/A - Cosmos Health Inc. (0001474167) (Subject)

      11/14/24 4:50:24 PM ET
      $COSM
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G filed by Cosmos Health Inc.

      SC 13G - Cosmos Health Inc. (0001474167) (Subject)

      2/14/24 3:33:29 PM ET
      $COSM
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13D/A filed by Cosmos Health Inc. (Amendment)

      SC 13D/A - Cosmos Health Inc. (0001474167) (Subject)

      7/25/23 4:06:11 PM ET
      $COSM
      Other Pharmaceuticals
      Health Care

    $COSM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Siokas Grigorios bought $102,000 worth of shares (254,618 units at $0.40), increasing direct ownership by 5% to 5,582,066 units (SEC Form 4)

      4 - Cosmos Health Inc. (0001474167) (Issuer)

      4/28/25 10:49:44 AM ET
      $COSM
      Other Pharmaceuticals
      Health Care
    • Chief Executive Officer Siokas Grigorios bought $71,000 worth of shares (177,234 units at $0.40), increasing direct ownership by 3% to 5,327,448 units (SEC Form 4)

      4 - Cosmos Health Inc. (0001474167) (Issuer)

      4/25/25 10:07:34 AM ET
      $COSM
      Other Pharmaceuticals
      Health Care
    • Chief Executive Officer Siokas Grigorios bought $82,000 worth of shares (205,000 units at $0.40), increasing direct ownership by 4% to 5,150,214 units (SEC Form 4)

      4 - Cosmos Health Inc. (0001474167) (Issuer)

      4/24/25 9:48:15 AM ET
      $COSM
      Other Pharmaceuticals
      Health Care

    $COSM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Siokas Grigorios bought $102,000 worth of shares (254,618 units at $0.40), increasing direct ownership by 5% to 5,582,066 units (SEC Form 4)

      4 - Cosmos Health Inc. (0001474167) (Issuer)

      4/28/25 10:49:44 AM ET
      $COSM
      Other Pharmaceuticals
      Health Care
    • Chief Executive Officer Siokas Grigorios bought $71,000 worth of shares (177,234 units at $0.40), increasing direct ownership by 3% to 5,327,448 units (SEC Form 4)

      4 - Cosmos Health Inc. (0001474167) (Issuer)

      4/25/25 10:07:34 AM ET
      $COSM
      Other Pharmaceuticals
      Health Care
    • Chief Executive Officer Siokas Grigorios bought $82,000 worth of shares (205,000 units at $0.40), increasing direct ownership by 4% to 5,150,214 units (SEC Form 4)

      4 - Cosmos Health Inc. (0001474167) (Issuer)

      4/24/25 9:48:15 AM ET
      $COSM
      Other Pharmaceuticals
      Health Care

    $COSM
    Financials

    Live finance-specific insights

    See more
    • Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000

      CHICAGO, April 30, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, has increased his stake in the Company by acquiring a total of 1,466,764 common shares, valued at $526,000, across five transactions between April 21, 2025, and April 24, 2025. As a result of these transactions, Mr. Siokas now beneficially owns 5,582,066 common shares in Cosmos Health. Greg S

      4/30/25 12:50:09 PM ET
      $COSM
      Other Pharmaceuticals
      Health Care
    • Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days

      CHICAGO, IL / ACCESS Newswire / January 21, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, has increased his stake in the Company by acquiring a total of 647,809 common shares, valued at $425,000, across six transactions between December 20, 2024, and January 17, 2025.As a result of these transactions, Mr. Siokas now beneficially owns 4,164,789 common shares in Cosmos Health.Greg Si

      1/21/25 3:00:00 PM ET
      $COSM
      Other Pharmaceuticals
      Health Care
    • Cosmos Health Issues Letter to Shareholders

      CHICAGO, IL / ACCESSWIRE / November 12, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its Chief Executive Officer, Greg Siokas, has issued the following letter to the Company's shareholders.Dear Cosmos Health Shareholders,It has been just over a year since my previous shareholder letter, and I would like to express my sincere gratitude for your continued support. We have achieved many positive milestone

      11/12/24 12:01:41 PM ET
      $COSM
      Other Pharmaceuticals
      Health Care

    $COSM
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $COSM
    Leadership Updates

    Live Leadership Updates

    See more

    $COSM
    SEC Filings

    See more
    • Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units

      CHICAGO, May 07, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has received an additional purchase order for 80,000 units from Pharmalink for its Sky Premium Life products in the United Arab Emirates (UAE). This latest order, pursuant to the exclusive distribution agreement with Pharmalink, follows the successful sell-out of the initial 130,000-unit purchase and supports the Comp

      5/7/25 2:30:10 PM ET
      $COSM
      Other Pharmaceuticals
      Health Care
    • Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq

      CHICAGO, May 06, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has received formal notice from the Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is eligible for an additional 180 calendar day period, through November 3, 2025, to regain compliance with the Nasdaq's minimum bid price requirement. As previously disclosed, on November 6, 2024, the Company was not

      5/6/25 1:40:33 PM ET
      $COSM
      Other Pharmaceuticals
      Health Care
    • Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000

      CHICAGO, April 30, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, has increased his stake in the Company by acquiring a total of 1,466,764 common shares, valued at $526,000, across five transactions between April 21, 2025, and April 24, 2025. As a result of these transactions, Mr. Siokas now beneficially owns 5,582,066 common shares in Cosmos Health. Greg S

      4/30/25 12:50:09 PM ET
      $COSM
      Other Pharmaceuticals
      Health Care
    • Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million

      CHICAGO, April 16, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today reported financial results for the full year ended December 31, 2024. Full Year 2024 Financial Highlights Income Statement: FY 2024 performance was marked by revenue growth, an increase in R&D investments, and a substantial reduction in operating expenses, while bottom-line results were impacted by the absence of non-recurring gain

      4/16/25 12:45:15 PM ET
      $COSM
      Other Pharmaceuticals
      Health Care
    • Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology

      CHICAGO, IL / ACCESSWIRE / December 26, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology at the Company's Research and Development division.Professor Trafalis currently serves as a Professor of Pharmacology and Clinical Pharmacology at the Faculty of Medicine, National and Kapodistrian University of Athens.He is a medical specialist in onc

      12/26/24 1:30:00 PM ET
      $COSM
      Other Pharmaceuticals
      Health Care
    • Cosmos Health Reports Q3 2023 Results; Revenue Increased 7% YoY, Total Assets Reached Record $71.5M with Stockholders' Equity of $44.2M or $3.4/Share

      THESSALONIKI, GREECE / ACCESSWIRE / November 21, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today provided a business update and reported financial results for the third quarter and nine months ended September 30, 2023.Third Quarter 2023 Financial HighlightsRevenues increased to $12.8 million from $12.0 million in Q3 2022, largely due to increased sales attributable to the logistics distribution business, which expanded

      11/21/23 9:00:00 AM ET
      $COSM
      Other Pharmaceuticals
      Health Care
    • Cosmos Health Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - Cosmos Health Inc. (0001474167) (Filer)

      5/7/25 1:30:41 PM ET
      $COSM
      Other Pharmaceuticals
      Health Care
    • SEC Form 10-K filed by Cosmos Health Inc.

      10-K - Cosmos Health Inc. (0001474167) (Filer)

      4/15/25 4:36:30 PM ET
      $COSM
      Other Pharmaceuticals
      Health Care
    • SEC Form NT 10-K filed by Cosmos Health Inc.

      NT 10-K - Cosmos Health Inc. (0001474167) (Filer)

      3/31/25 4:33:37 PM ET
      $COSM
      Other Pharmaceuticals
      Health Care